Trials / Completed
CompletedNCT00192517
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI-522 | 4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0) |
| OTHER | Placebo | 4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0) |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2004-08-01
- Completion
- 2004-09-01
- First posted
- 2005-09-19
- Last updated
- 2009-04-03
Locations
20 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00192517. Inclusion in this directory is not an endorsement.